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FIG. 1.
Immunoprecipitation analysis of the reaction between purified human erythrocyte PP-ribose-P synthetase and rabbit serum. Center well contained 25 Al of 5000-fold purified normal PP-ribose-P synthetase (460 Mg/ml). Numbered wells contained the following: wells 1 and 6, serum from immunized rabbits; wells 2 and 5, serum from unimmunized rabbits; wells 3 The intracellular availability of the sugar phosphate, 5-phosphoribosyl 1-pyrophosphate (PP-ribose-P), is an important factor in regulation of the rate of purine synthesis de novo in humans (1) . The interactions of this compound and purine nucleotides at allosteric sites on PP-ribose-P amidotransferase appear to control the activity of this, the first committed and rate-limiting, enzyme of purine synthesis de novo (2) . Thus, the increased rate of purine synthesis associated with deficiency of hypoxanthine phosphoribosyltransferase (3) can be explained by the increased intracellular concentration of PP-ribose-P demonstrated in fibroblasts (4), lymphoblasts (5), erythrocytes (6) , and neuroblastoma cells (Wood, A. W., Becker, M. A., Minna, J., & Seegmiller, J. E., unpublished work) deficient in this enzyme.
Recently two families have been described in which excessive purine production and clinical gout have been associated with increased activity of PP-ribose-P synthetase (EC 2.7.6.1), the enzyme that catalyzes the synthesis of PPribose-P from ATP and ribose-5-phosphate (7, 8 ). An increased capacity to generate PP-ribose-P has been demonstrated in erythrocytes from affected members of both families and in cultured fibroblasts from one of the affected individuals (8) . We have, in addition, found increased erythrocyte and fibroblast PP-ribose-P concentrations and increased purine biosynthetic rates both in fibroblasts and in our patients in vivo (8) . Purine overproduction in these individuals appears to result from increased intracellular generation of the regulatory substrate PP-ribose-P due to a hereditary increase in PP-ribose-P synthetase activity.
Since an inherited increase in enzyme activity is unusual, particularly in association with human disease states (9), we sought to define further the molecular basis of this enzyme aberration. The possible molecular mechanisms underlying increased enzyme activity have been reviewed (8) . Our previous studies indicated that increased PP-ribose-P synthetase activity in affected members of the B. family resides in the enzyme protein rather than in altered concentrations of effector molecules (8) . Furthermore, studies of thermal lability, affinity constants, inhibitory constants, and phosphate activation in crude extracts did not provide evidence for a structural alteration in the patients' enzyme (10). The results of these studies were consistent with (i) normal quantities of structurally altered enzyme of increased activity per molecule; (ii) increased amounts of structurally normal or altered enzyme resulting from either increased synthesis or decreased degradation, or (iii) some combination of the first two possibilities. In the present study we report immunochemical and electrophoretic evidence for a structurally altered PP-ribose-P synthetase with increased activity per molecule in affected members of the B. family.
MATERIALS AND METHODS
Preparation of Antiserum. Erythrocyte PP-ribose-P synthetase was purified 5000-fold from 2 units of outdated normal human blood by the method of Fox and Kelley (11) . The enzyme, in incomplete Freund's adjuvant, was injected subcutaneously into the footpads of two rabbits. After an initial dose of 350 Mg, 6 weekly injections of 100 lug were given.
Serum obtained from each animal was passed through a 0.45-;sm Millipore filter and heated at 560 for 30 min. The sera were centrifuged at 10,000 X g for 30 min, and samples of the supernatant layers were tested against purified enzyme by gel diffusion in 1.5% agar (12) . Serum from each immunized rabbit gave a single precipitin band while control unimmunized rabbit serum gave none (Fig. 1) . Whole serum from both immunized and unimmunized rabbits inactivated PP-ribose-P synthetase. For this reason, the IgG fraction of the serum was isolated by collection of the material passing directly through a DEAE-cellulose column equilibrated with 0.01 M phosphate buffer (pH 8.0) and then concentrated by ultrafiltration with an Amicon XM100A filter. The purified material was identified as IgG by immunoelectrophoresis (13); the fraction isolated from immunized rabbits showed a weaker 2749 Abbreviation: PP-ribose-P, 5-phosphoribosyl 1-pyrophosphate.
FIG. 1.
Immunoprecipitation analysis of the reaction between purified human erythrocyte PP-ribose-P synthetase and rabbit serum. Center well contained 25 ,ud of 5000-fold purified normal PP-ribose-P synthetase (460 Mg/ml). Numbered wells contained the following: wells 1 and 6, serum from immunized rabbits; wells 2 and 5, serum from unimmunized rabbits; wells 3 and 4, IgG fractions from unimmunized and immunized rabbits, respectively. Double diffusion was done for 24 hr at 4°. Single precipitin bands are noted only where outer wells contained immunoglobulin from rabbits immunized with the purified enzyme.
but definite precipitin band when tested against purified enzyme (Fig. 1) . The concentrated IgG fraction from immunized rabbits inactivated PP-ribose-P synthetase at protein concentrations well below those needed for inactivation by the comparable fractions from unimmunized rabbits (Fig. 2) . All immunologic experiments reported below were done with the concentrated IgG fraction from the serum of immunized animals with the comparable fraction from unimmunized rabbits serving as controls.
Electrophoresis. PP-Ribose-P synthetase, purified 50-to 90-fold by use of the DEAE-cellulose batch elution described by Fox and Kelley (11) ultrafiltration with an Amicon XM100A filter and applied to Cellogel cellulose acetate strips. Electrophoresis was done at 40 for 45 min at 400 V in a 40 mM barbital-10 mM phosphate buffer solution containing 10 mM reduced glutathione and mM magnesium chloride with a final pH of 8.6. The gels were then immediately stained at 370 for PP-ribose-P synthetase activity by a modification-of the method of Katzen (14) to be described elsewhere (Switzer, R. L., Rosenzweig, S., Becker, M. A. & Seegmiller, J. E., unpublished work). In brief, the staining method depends on generation of ATP from PP-ribose-P and AMP by PP-ribose-P synthetase. The ATP generated is a substrate in the hexokinase reaction which is linked to NADPH production by addition of glucose-6-phosphate dehydrogenase. Color production depends directly on reduction of nitro blue tetrazolium to a formazan with phenazine methosulfate acting to transfer electrons to the artificial acceptor (15) . Control gels are treated in an identical fashion except that PP-ribose-P is omitted from the staining solution.
Other Methods. PP-ribose-P synthetase was assayed by the two-step method described by Fox and Kelley (11) except that the inorganic phosphate concentration in the first step was 32.0 mM and labeled adenosine 5'-monophosphate in the second step was isolated by cellulose thin-layer chromatography (5). Protein determinations were made by the method of Lowry et al. (16) . RESULTS
Immunochemical Studies. The concentrated IgG fraction prepared from immunized rabbits inhibited PP-ribose-P synthetase activity in dialyzed erythrocyte lysates (Fig. 2) . Inhibition of enzyme activity was incomplete-reaching a plateau at between 10 and 20% of initial activity depending upon the particular preparation of concentrated IgG used. In view of the extremely small amounts of enzyme protein involved in the neutralization of activity (Fig. 2) Increased PP-Ribose-P Synthetase Activity 2751 synthetase in the enzyme-antibody complex. This suggestion is supported by the observation that centrifugation of the reaction mixture in the neutralization studies at 48,000 X g for 1 hr failed to yield chemically detectable protein precipitates.
A distinct difference is apparent when neutralization of PPribose-P synthetase activity of dialyzed hemolysates from normal individuals and from patient T.B. is compared. Addition of increasing amounts of antiserum to hemolysates matched for protein concentration (in which T.B.'s enzyme activity is 2.7-times that of the normal) results in the pattern of inactivation depicted in Fig. 3A . The same volume of antiserum appears to inactivate more than 2.5-times as much PP-ribose-P synthetase activity from patient T.B. than from the normal individual. The plateau is reached in each case after addition of nearly identical amounts of antiserum. When the hemolysates are matched for PP-ribose-P synthetase activity, protein concentration being 2.7-times greater in the normal extract, inactivation of patient T.B.'s enzyme reaches plateau after addition of less than half as much antiserum as required for the normal enzyme (Fig. 3B) . These findings suggest that enzymes from the two sources differ by more than 2.5-fold in activity per immunologically reactive unit (enzyme molecule), patient T.B.'s enzyme being the more active.
Addition of increasing amounts of dialyzed normal or mutant hernolysate to a fixed amount of antiserum results in a pattern of enzyme activity shown in Fig. 4A and B. The lines obtained in the presence of immunized rabbit IgG show two components for activities of both normal individuals and patient T.B. The initial component of each is once again most consistent with residual enzyme activity in the enzymeantibody complex. Despite, in this case, a 3-fold difference in activities between normal and mutant hemolysates, the point at which unbound enzyme activity appears ("equivalence point") is very nearly identical in both cases (arrows in Fig. 4 ). When each point on these lines is compared to its control inwhich IgG obtained from unimmunized rabbits replaces immunized rabbit IgG ( Fig. 4A and B) , the proportion of PPribose-P synthetase activity neutralized by the antiserum is nearly identical for patient T.B. and for normal individuals.
These results have been confirmed in dialyzed extracts of fibroblasts cultured from normal individuals and from T.B., indicating the presence of equal amounts of immunoreactive PP-ribose-P synthetase in the normal and mutant cells despite the observed disparity in enzyme activities.
Electrophoretic Studies. The electrophoretogram shown in Fig. 5 demonstrates a difference in migration on cellulose acetate gel between partially purified erythrocyte PP-ribose-P synthetase from patient T.B. and from two normal individuals. When compared with the control gel in which PPribose-P is omitted from the staining solution, the normal enzyme is seen to migrate as a single band significantly proximal to the clear zone (which probably represents a dehydrogenase). In contrast, PP-ribose-P synthetase from patient T.B. migrates as a single band that partially overlies the clear zone and is separable from the normal enzyme. When partially purified extracts from control subjects and from patient T.B. are mixed, the separation of the normal and mutant bands is confirmed; Among 12 normal individuals, no variation in PPribose-P synthetase migration on cellulose acetate gel has been found for the partially purified erythrocyte enzyme.
DISCUSSION
Genetically transmitted alterations in enzyme function in humans are usually characterized by diminished enzyme activity. Although increased enzyme activity has been described in several instances (7, 8, (17) (18) (19) (20) (21) , evidence that an excess of enzyme activity is the primary genetic defect in any human disease state is restricted to the case of increased PP-ribose-P synthetase activity in certain patients with gout (7, 8) . In the two families in which this association has been described, moreover, the molecular basis for the increased enzyme activity is clearly different (7, 10) . While Sperling and de Vries have found altered response to nucleotide inhibition in the erythrocyte PP-ribose-P synthetase of their affected family members (22) , our immunochemical studies indicate an en-zyme with intrinsically increased activity per molecule in cells from affected members of the B. family.
Previously characterized examples of genetically determined increased enzyme activity in human cells have proved to result from increased synthesis of structurally altered enzyme with normal activity per molecule (17, 18) , from altered concentrations of small-molecule effectors of enzyme activity (19, 20) , or from macromolecular or small-molecule stabilization of enzyme activity (20, 21) . Previous studies with PPribose-P synthetase from affected members of the B. family showed neither small-molecule effectors nor stabilizers to explain the increased enzyme activity (10) . The demonstration here of increased PP-ribose-P synthetase activity per molecule of enzyme in the absence of evidence for an increased quantity of PP-ribose-P synthetase appears sufficient to explain the excessive activity found in cells of affected members of the B. family.
In previous studies in dialyzed erythrocyte hemolysates, we were unable to demonstrate evidence for a structural difference between PP-ribose-P synthetase of normal individuals and of the B. family (10) . The development of a specific stain for PP-ribose-P synthetase activity, however, has allowed us to demonstrate an electrophoretic difference between PPribose-P synthetase from patient T.B. and from normal individuals. Both the electrophoretic and immunochemical studies strongly suggest a structural alteration in PP-ribose-P synthetase of the B. family which leads to increased enzyme activity per molecule. The primary molecular basis for this previously undescribed form of human genetic alteration in enzyme function will be of further interest.
